1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Affectis Pharmaceuticals AG - Product Pipeline Review - 2013

Affectis Pharmaceuticals AG - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 26 pages

Affectis Pharmaceuticals AG - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Affectis Pharmaceuticals AG - Product Pipeline Review - 2013” provides data on the Affectis Pharmaceuticals AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Affectis Pharmaceuticals AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Affectis Pharmaceuticals AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Affectis Pharmaceuticals AG - Brief Affectis Pharmaceuticals AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Affectis Pharmaceuticals AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Affectis Pharmaceuticals AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Affectis Pharmaceuticals AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Affectis Pharmaceuticals AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Affectis Pharmaceuticals AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Affectis Pharmaceuticals AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Affectis Pharmaceuticals AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Affectis Pharmaceuticals AG and identify potential opportunities in those areas.

Table Of Contents

Affectis Pharmaceuticals AG - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Affectis Pharmaceuticals AG Snapshot 4
Affectis Pharmaceuticals AG Overview 4
Key Information 4
Key Facts 4
Affectis Pharmaceuticals AG - Research and Development Overview 5
Key Therapeutic Areas 5
Affectis Pharmaceuticals AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
Affectis Pharmaceuticals AG - Pipeline Products Glance 11
Affectis Pharmaceuticals AG - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Affectis Pharmaceuticals AG - Drug Profiles 13
AFC-5128 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
AFC-5261 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
AFC-08 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
AFC-5278 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Affectis Pharmaceuticals AG - Pipeline Analysis 17
Affectis Pharmaceuticals AG - Pipeline Products by Therapeutic Class 17
Affectis Pharmaceuticals AG - Pipeline Products by Target 18
Affectis Pharmaceuticals AG - Pipeline Products by Route of Administration 19
Affectis Pharmaceuticals AG - Pipeline Products by Molecule Type 20
Affectis Pharmaceuticals AG - Pipeline Products by Mechanism of Action 21
Affectis Pharmaceuticals AG - Recent Pipeline Updates 22
Affectis Pharmaceuticals AG - Dormant Projects 23
Affectis Pharmaceuticals AG - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26



List of Tables

Affectis Pharmaceuticals AG, Key Information 4
Affectis Pharmaceuticals AG, Key Facts 4
Affectis Pharmaceuticals AG - Pipeline by Indication, 2013 6
Affectis Pharmaceuticals AG - Pipeline by Stage of Development, 2013 7
Affectis Pharmaceuticals AG - Monotherapy Products in Pipeline, 2013 8
Affectis Pharmaceuticals AG - Out-Licensed Products in Pipeline, 2013 9
Affectis Pharmaceuticals AG - Out-Licensed Products/ Combination Treatment Modalities, 2013 10
Affectis Pharmaceuticals AG - Preclinical, 2013 11
Affectis Pharmaceuticals AG - Discovery, 2013 12
Affectis Pharmaceuticals AG - Pipeline by Therapeutic Class, 2013 17
Affectis Pharmaceuticals AG - Pipeline by Target, 2013 18
Affectis Pharmaceuticals AG - Pipeline by Route of Administration, 2013 19
Affectis Pharmaceuticals AG - Pipeline by Molecule Type, 2013 20
Affectis Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2013 21
Affectis Pharmaceuticals AG - Recent Pipeline Updates, 2013 22
Affectis Pharmaceuticals AG - Dormant Developmental Projects,2013 23



List of Figures

Affectis Pharmaceuticals AG - Pipeline by Top 10 Indication, 2013 6
Affectis Pharmaceuticals AG - Pipeline by Stage of Development, 2013 7
Affectis Pharmaceuticals AG - Monotherapy Products in Pipeline, 2013 8
Affectis Pharmaceuticals AG - Pipeline by Top 10 Therapeutic Class, 2013 17
Affectis Pharmaceuticals AG - Pipeline by Top 10 Target, 2013 18
Affectis Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2013 19
Affectis Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2013 20
Affectis Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2013 21



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.